Extrapyramidal adverse symptoms (EPS) represent a major type of adverse events in treatment with typical antipsychotic drugs which share high affinity to the dopamine D 2 receptor (DRD2). Genetic variants of this receptor may modulate the therapeutic response and the severity of adverse symptoms of antipsychotics. We analyzed nine known polymorphisms of the DRD2 in 665 schizophrenic patients with European Caucasian ethnic background and compared the intensity of acute dystonia, extrapyramidal symptoms, akathisia, and tardive dyskinesia between carriers of different DRD2 genotypes. In a subgroup of 40 patients with most severe extrapyramidal symptoms we sequenced the coding region including the exonintron junctions of the DRD2 gene. Functionally relevant DRD2 amino acid variants (Ser 310 , Cys 311 ) were rare or were not found at all (Ala 96 ). Complete sequence analysis of sufferers from the most severe adverse effects revealed two new intronic polymorphisms and a silent polymorphism in exon 7, but no new amino acid variants beyond those which are already known. We found no significant association between these polymorphisms and the intensity of the different types of adverse neurologic effects of the antipsychotics. These results were obtained by correlating adverse events with each of the nine single nucleotide polymorphisms and by correlation with the estimated haplotypes. In conclusion, genetic variations in the DRD2 gene were no major predictors of the individually variable adverse effects from antipsychotic treatment in Caucasian schizophrenic patients.
Introduction
Administration of typical antipsychotics in the treatment of schizophrenia is associated with a high rate of undesirable neurologic effects such as acute dystonia, pseudoparkinsonism (EPS), akathisia and tardive dyskinesia. These may be observed in up to 50-75% of patients and may require discontinuation of treatment in up to 10% of patients. 1, 2 Antidopaminergic drugs produce acute dystonia and pseudo-parkinsonian symptoms and in a subgroup of long-term or high-dose treated patients these symptoms may persist after discontinuation of the medication in the form of tardive dyskinesia. 3, 4 It has been hypothesized that neuroleptics irreversibly desensitize and depopulate dopaminergic receptors 5 or that they increase the neuronal firing rates and release of nigro- 6, 7 Akathisia is a frequent adverse effect of antipsychotic treatment and is characterized by periodic movements of the legs and inner restlessness. A dopaminergic misbalance may be the underlying mechanism since the occurrence of akathisia was related to D 1 and D 2 receptor occupancy. [8] [9] [10] Tardive dyskinesia is a later and most pronounced adverse event appearing as abnormal, involuntary, irregular, repetitive movements of the orofacial musculature and limbs found in approximately 25% of patients. Alteration in the dopamine D 1 or D 2 receptor mediated striatonigral or striatopallidal pathways and a loss of striatal neurons might be involved in the pathogenesis indicating a neurotoxic effect of longterm antipsychotic treatment. 11, 12 The dopamine D 2 receptor (DRD2) is the primary binding target of all typical antipsychotics. It belongs to the family of receptors coupled to heterotrimeric cyclic guanine nucleotide binding regulatory proteins (G-proteins). The DRD2 activates intracellular signaling by inhibition of cAMP synthesis through interaction with G i -like proteins. As shown in Figure 1 , the DRD2 Figure 1 The genomic structure and the examined polymorphisms of the DRD2 receptor gene. Boxes represent the exons. Shadowed boxes represent the coding sequences within the exons. Transmembrane domains (I-VII) were characterized by black boxes. All polymorphisms are indicated with their respective localization according to the published sequence. 13 Polymorphisms indicated by * have been found by sequencing in the subgroup of 40 individuals with the severest EPS.
gene has eight exons and spans at least 270 kb. The presumed promoter sequence is separated by the large (greater than 250 kb) first intron from the proteincoding sequence. 13, 14 Several variants of the DRD2 gene are known: one substitution (Val 96 Ala) within the second transmembrane domain and two substitutions (Pro 310 Ser, Ser 311 Cys) within the third transmembrane domain and a number of silent polymorphisms. 15 Previous studies using positron emission tomography (PET) have shown that a threshold DRD2 occupancy of about 65-75% during antipsychotic treatment is necessary to obtain a therapeutic effect. 16 Individuals with the TaqIA1 and TaqIB1 allele were shown to have a decreased striatal DRD2 density and showed a better clinical response to a DRD2 antagonist. [17] [18] [19] [20] In contrast, individuals with the −141C insertion allele of the promoter showed an increased DRD2 density. 17 Moreover, in vitro the Ala 96 variant had a 50% reduced binding affinity for clozapine, chlorpromazine and dopamine whereas the Cys 311 and Ser 310 variants were markedly less effective in inhibiting cAMP synthesis than the wild-type or the Ala 96 variant. 21, 22 Therefore, these variations in the DRD2 receptor gene might explain individual differences in the susceptibility to develop adverse drug effects in schizophrenic patients. We tested this hypothesis in a multicenter prospective trial in patients receiving typical antipsychotic drugs.
Materials and methods

Subjects
A hospital-based, multicenter, naturalistic, prospective, non-interventional study was performed with unrelated schizophrenic patients from Berlin, Germany. We recruited 665 schizophrenic patients (53.6% male, 46.4% female) with a mean age of 38.3 years (range 18-70 years, SD = 12.1) and a median age of onset of 28.7 years (range 14-66 years, SD = 9.1) from two university psychiatric hospitals in Berlin (Universitätsklinikum Charité and Universitätsklini-kum Benjamin Franklin) and from three community psychiatric hospitals (Wilhelm-Griesinger Krankenhaus, Kliniken im Theodor Wenzel Werk, UrbanKrankenhaus). Only subjects of German Caucasian descent were included.
Patients with organic or drug-induced psychosis as revealed by clinical history, magnetic resonance tomography, computerized tomography, or toxicological laboratory findings and patients younger than 18 or older than 70 years were excluded. Not all patients could be evaluated by the rating scales given below because they were either not able to participate in the neurological tests for adverse effects or were dismissed prior to the respective test dates from the hospitals within a few days after admission to the hospital. In addition, we excluded all patients with repeated admission to the hospital during the study period. Of the 665 patients initially recruited, we could analyze the different scores for the adverse effects from 584 patients at observation point day 2-4, from up to 518 patients at day 12-16 and from up to 390 patients at day 26-30. To explore the bias possibly caused by those who could not be explored for adverse events, we compared the genotype frequencies in both groups (those who completed the evaluation and those who did not complete the evaluation), but no significant differences were found by use of the chi-square test. This result excludes at least a major selection bias. Informed consent was obtained from all subjects. The study was approved by the Ethics Committee of the Universitäts-klinikum Charité (Humboldt-Universität zu Berlin) and the Universitätsklinikum Benjamin Franklin (Freie Universität Berlin).
All 665 patients were acute hospitalized patients with schizophrenia according to DSM-IV criteria, including 368 schizo-paranoid (DSM-IV 295.3), 134 schizo-affective (295.7), 45 residual (295.6), 41 catatonic (295.2), 23 disorganized (295.1), 11 schizophrenic form (295.4), six undifferentiated (295.9), and 37 other and unclassified subtypes. Diagnosis was assigned on the basis of interviews and medical records according to DSM-IV criteria. All psychiatrists involved in the study received detailed instructions on how to apply the DSM-IV criteria prior to the study. Age at first episode, duration, familial predisposition, number of recurrent exacerbations, smoking behavior and current therapeutic response (using the positive and negative symptoms scale), and medication were documented. Incident cases were 131 patients and 534 patients suffering from recurrent exacerbation.
Adverse effects of antipsychotics were evaluated for the extent of acute dystonia using an adverse effect reporting form. The extrapyramidal symptoms (pseudoparkinsonism) were recorded by the Extrapyramidal Symptom Scale (EPS) published by Simpson and Angus. 23 Akathisia was described by the Barnes Akathisia Rating Scale (BARS). 24 Tardive dyskinesia was measured by use of the Abnormal Involuntary Movement Scale (AIMS). 25 Besides the formal criterion for tardive dyskinesia, 26 the raw AIMS score was used without data reduction. Interviews took place on day 3 (2-4), day 14 (12) (13) (14) (15) (16) and day 28 (26) (27) (28) (29) (30) after admission to the hospital. Inter-rater reliability was assured by regular monthly meetings of the clinical investigators.
Of the typical antipsychotics, haloperidol, flupenthixol, clopenthixol, perazine, and fluphenazine were administered most frequently. Applied dosages at the day of examination were calculated as chlorpromazine adjusted dosage: therefore dosages of haloperidol were multiplied by 50, flupenthixol by 30, clopenthixol by 6, perazine by 1.2 and fluphenazine by 50. The attending psychiatrists were blinded with respect to the patients genotype.
Methods
High-molecular-weight genomic DNA was prepared from venous blood using the standard phenol chloroform extraction. Laboratory staff was blind to the psychiatric observations. Analysis for the −241AϾG and −141C insertion/deletion polymorphism of the DRD2 gene was modified from Arinami et al 27 All PCR-products were digested with restriction enzymes according to the manufacturer's protocol, separated by 3.0% agarose gel electrophoresis and stained with ethidium bromide for UV visualization.
Sequence analysis
For sequencing we first amplified exons 3-5 (10× buffer 1, initial denaturation at 94°C for 2 min, followed by 35 cycles of 96°C for 10 s, 61°C for 20 s, 68°C for 3 min and a final extension period of 72°C for 7 min) and exons 6-8 (10× buffer 2, initial denaturation at 94°C for 2 min, followed by 35 cycles of 96°C for 10 s, 62°C for 20 s, 68°C for 5 min and a final extension period of 72°C for 7 min) using the Expand Long Template PCR system (Roche, Germany) and the respective primers (exon 3-5: primer pair 3.1, 5.2; exon 6-8: primer pair 6.1, 8.2, Table 1 ). Exon 2 was amplified using the primer pair 2.1, 2.2 and the following PCR cycle conditions: initial denaturation at 94°C for 2 min, followed by 35 cycles of 95°C for 20 s, 60°C for 20 s, 72°C for 1 min and a final extension period of 72°C for 7 min.
The following sequencing reaction was carried out with exon specific primers as shown in Table 1 : the PCR cycle sequencing program consisted of an initial denaturation at 94°C for 2 min, followed by 25 cycles with an initial denaturation at 96°C for 15 s, annealing at 57°C for 15 s, extension at 60°C for 4 min and a final extension period of 72°C for 7 min using a GeneAmp 9600 Perkin-Elmer Cetus PCR machine. Analysis was performed using a Big-Dye Primer cycle sequencing kit on a ABI 310 automated capillary DNA sequencer (Perkin Elmer, USA) and compared with the published sequence (GenBank accession number AF050737).
Statistical methods
All statistical analyses were performed by the SPSS, Version 8.01 software. Significance of frequency differences of the different genotypes was assessed by Pearson's 2 test or, if any cell count was less than 5, by Fisher's exact test. The limit of significance was set to 0.05. Correlation analysis to search for relationships between the intensity of the EPS-, AIMS-and BARSscores and the potential clinical predictors or polymorphisms of the DRD2 was conducted using the Spearman rank test. Effects of the different DRD2 genotypes on drug effects measured by the EPS-, AIMS-and BARS-scores were analyzed using the Kruskal-Wallis test, the Mann-Whitney U-test (two sided) and the Jonckhere-Terpstra test (two sided). Logistic regression analysis was performed to elucidate the association between scores of EPS, AIMS and BARS and the DRD2 polymorphisms taking age, sex, chlorpromazineadjusted dose, dose of anticholinergic drugs, number of recurrent exacerbations and smoking simultaneously into account. For this purpose, patients were grouped into subgroups with low and high scores of the rating scales. Linkage disequilibrium and estimated haplotypes were assessed using the linkage utility program Equilibrium Haplotype (EH).
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Results
As shown in Figure 1 and 2) disclosed no significant differences for the frequencies of the tested genotypes (Table 2) . We did not find any relationship between the DRD2 receptor genotypes with family history, number of recurrent exacerbations or age at the first manifestation. Sequencing of the protein coding DRD2 exons 2-8 including the exon-intron junctions from genomic DNA of the 40 patients with the most severe EPS out of 584 patients with data for the Simpson Angus scale Del, deletion; ins, insertion. revealed no new amino acid variants, but a number of silent polymorphisms, as shown in Table 3 .
As shown in Table 4 there was a significant correlation between chlorpromazine adjusted dose taken within 24 h before scoring and the intensity of pseudoparkinsonian symptoms. Intensity of the EPS-score was significantly correlated with the chlorpromazine adjusted dosage and dose of biperiden (P Ͻ 0.001 for every date of examination); biperiden was the almost exclusively administered anticholinergic agent. We did not find an association between the EPS-score and age, For the AIMS-score, there was a significant correlation with age (P Ͻ 0.001 for every date of examination) and number of recurrent exacerbations (P Ͻ 0.001 for every date of examination). Intensity of the BARS-score was significantly correlated with the number of recurrent exacerbations (P Ͻ 0.001 at day 2-4, P Ͻ 0.05 at day 12-16) and with chlorpromazine adjusted dosage (P Ͻ 0.06 at day 2-4, P Ͻ 0.005 at day 12-16, P = 0.01 at day 26-28).
Analysis of the severity of the extrapyramidal symptoms in relation to the DRD2 genotypes did not show any statistically significant correlation (Table 5) . But, patients heterozygous for the Ser 310 allele (n = 3) had a trend to lower mean value of EPS-score than patients homozygous for the Pro 310 allele. Mean of the EPS-score at day 2-4 after start of therapy was 2.3 in heterozygous carriers of the Ser 310 variant compared with 4.6 in those homozygous for the Pro 310 allele. The relationship was similar at the two subsequent examinations with a mean EPS score of 2.7 vs 4.6 at day 14 and 1.0 vs 4.5 at day 28.
The individual cumulative doses of anticholinergic drugs were used as an additional parameter reflecting acute dystonia and pseudoparkinsonism. Biperiden was almost the only anticholinergic drug used in the participating hospitals and the correlation of the cumulative dose of biperiden with the eight DRD2 polymorphisms did not reveal any significant association.
There was no significant association of any DRD2 genotype with the severity of AIMS (Table 5) . But patients heterozygous for the Ser 310 allele showed a 0 vs 2.0) . For the Ser 311 Cys polymorphism we could not observe a significant difference in the intensities of the EPS-score stratified for the respective genotypes.
As shown in Table 5 patients heterozygous for the Cys 311 allele had decreased mean values of the AIMSscore compared with individuals homozygous for the Ser 311 allele at day 2-4 (mean value: 0.8 vs 1.8) and day 28 (mean value: 0.8 vs 1.5). The mean value of the applied chlorpromazine adjusted dosages between these patients stratified for the genotypes did not differ significantly.
Patients homozygous for the TaqIA1 allele (the allele reported to be associated with decreased receptor density) showed a trend to lower EPS-scores than patients heterozygous or homozygous for the TaqIA2 allele, especially in the subgroup of males: mean value of the EPS score at day 2-4 was 2.4 in patients homozygous for the TaqIA1 allele compared with 4.9 in individuals homo-or heterozygous for the TaqIA2 allele (statistically not significant). The two subsequent examinations showed the same tendency with a median of the EPS score of 3.4 vs 4.5 at day 14 and 3.3 vs 4.7 at day 28. The same tendency could be observed for the TaqIB polymorphism. The mean value of the applied chlorpromazine adjusted dosages between patients stratified for the different genotypes of these polymorphisms differed not significantly.
In contrast to EPS-score, patients homozygous or heterozygous for allele 2 of the TaqIA polymorphism showed a trend to lower mean value of the BARS score compared with patients homozygous for the allele 1, especially in the subgroup of males (day 2-4: median of the BARS score: 2.0 vs 2.0, at day 14: 1.0 vs 5.0, at day 28: 0.0 vs 2.8). The same tendency could be observed for the linked TaqIB polymorphism.
In addition using logistic regression analysis we found no significant association between scores of EPS, AIMS and BARS as dependent variable and the different DRD2 polymorphisms taking age, gender, chlorpromazine adjusted dose, dose of anticholinergic agents, number of recurrent exacerbations and smoking simultaneously into account.
The eight polymorphic loci within or near the DRD2 gene are partially linked. The estimation of the chromosomal organization showed that three haplotypes accounted for over 80% of all haplotypes. As shown in Table 6 , there was no significant difference in the frequency of the estimated haplotypes between The frequency of the estimated haplotypes assuming association and the respective allelic organization in % within the respective group of adverse effects are presented. Del, deletion; ins, insertion; EPS, rating scale for pseudoparkinsonism; BARS, rating scale for akathisia; AIMS, rating scale for tardive dyskinesia.
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patients with higher rating scores of adverse effects compared with patients with lower scores. The analysis presented in Table 6 refers to the measurements at day 2-4. The corresponding analysis was performed at the two other observation points (days 12-16 and 26-30) but again, no differences were found. As shown in Table 7 , all TaqI-polymorphisms (TaqIA, B, D) were in strong linkage disequilibrium with each other and linked with the −141CIns/Del polymorphism. Moreover the TaqID polymorphism was linked with the −241AϾG variant and the Ser 311-Cys polymorphism. About 512 possible estimated two locus haplotypes could be found for these nine loci for the entire study population of 665 patients ( 2 = 1597.47, P Ͻ 0.001, df = 511) by using the linkage utility program. 33 Six haplotypes accounted for over 80% of the haplotypes (Table 6 ).
Discussion
We wanted to explore whether genetic variants in the DRD2 gene may predict adverse effects of drug treatment with DRD2 antagonists. However, we failed to detect a statistically significant association with nine single nucleotide polymorphisms or with the haplotypes. In the subgroup of patients suffering from the most severe adverse events we did not detect any new amino acid variants or other variants for which functional relevance might be deduced from genotype.
As expected, significant correlations could be observed between the chlorpromazine adjusted dosage and extrapyramidal symptoms or akathisia. The number of recurrent exacerbations was significantly correlated with intensity of involuntary movements (reflecting tardive dyskinesia) or with akathisia. Moreover, age was correlated with the intensity of involun- tary movements. These clinical predictors of adverse events (Table 2) have been described earlier. [34] [35] [36] Since typical antipsychotics mediate their adverse events via the dopamine D2 receptor, altered signal transduction by DRD2 variants may result in alterations of the intensities of these adverse events. For most of the polymorphisms studied here there is some evidence about functional and medical impact. For the TaqIA polymorphism, individuals either homo-or heterozygous for the TaqIA1 allele appear to have lower DRD2 density, [17] [18] [19] but this finding is controversial. 37 Moreover, these patients showed a better therapeutic response. 20 However, in agreement with Mihara et al 38 we could not find a significant association between adverse events measured by the EPS-score and the TaqIA 1 allele.
Chen et al 39 showed that females homozygous for the TaqIA2 allele had a higher risk for tardive dyskinesia compared to females carrying the TaqIA1 allele. We could not find such an association, either in the subgroup of females with and without dyskinesia or between incident patients and patients with recurrent exacerbations of the disease; females homozygous for the TaqIA2 allele showed lower intensities of the AIMS score. Nevertheless it remains questionable, whether and how much the TaqIA polymorphism modulates the expression of the DRD2 receptor, since this polymorphism is located 10 kb upstream of the 3Ј non coding region of the gene. To explain the positive findings it was argued that this polymorphism may be linked with an unknown functional mutation of the promotor region which might influence the expression of the gene. However, the only discussed functional promotor variant of the DRD2 which is linked with the TaqIA polymorphism is the −141C insertion variant ( Table 7) .
The deletion variant of the of the −141C insertion/deletion polymorphism of the promoter may reduce the protein expression in vitro. 27 It was hypothesized that the increased DRD2 density in the brain of schizophrenic patients may be explained in part by this promoter variant. Some authors reported an association of this variant with schizophrenia, however, others could not confirm these observations. 27, [40] [41] [42] [43] In accordance with this, the results of DRD2 density studies in humans are contradictory. 17, 44 In our sample the frequency of this deletion variant was similar compared to other Caucasian samples [40] [41] [42] [43] and we could not detect any association between this polymorphism and the clinical intensity of adverse events. In contrast to Ohara et al, 45 we could not find a difference in the age of first manifestation of the disease stratified for the different genotypes. Reports in Caucasians showed either the opposite 41 or no association. 42, 43 We could not find any individual with the Ala 96 variant, as confirmed by two different PCR-assays. Moreover, no individual in the group analyzed by DNA sequencing showed this mutation. Gejman et al 46 described this variant in a single Caucasian woman with alcohol dependence and drug abuse and the Ala 96 variant showed an up to 50% reduced binding affinity for clozapine, chlorpromazine and dopamine in vitro 21, 22 but this variant is apparently extremely rare in Caucasians.
The Pro 310 Ser variant resides in the cytoplasmatic third loop of the receptor protein. In vitro data showed a less effective inhibition of the cAMP synthesis for the Ser 310 variant upon exposure to various antipsychotics in comparison with the wild type. 22 In our study only three individuals were heterozygous for the Ser 310 variant. Two other authors have investigated this variant in patients with alcoholism and found a similarly low frequency as in our population. 31, 46 The heterozygous individuals of our study did not show any special phenotype. All three were characterized as schizoparanoid and only one patient had a family history of schizophrenia. The mean age of first manifestation was 26.7 years (SD: 2.5) and was not different from those homozygous for the Pro 310 allele (mean age 28.7 years, SD: 9.1). With respect to side effects, we observed a consistent trend: patients heterozygous for the Ser 310 allele showed lower EPS-, AIMS-and BARS-scores than patients homozygous for the Pro 310 allele.
The Ser 311 Cys polymorphism is also located in the G-protein coupling region. The Cys 311 variant was markedly less effective in inhibiting cAMP synthesis than the wild type and the Ser 310 variant. 21, 22 In the current study the frequency of Cys 311 was 4.7% in heterozygous individuals. In previous reports the fre-quency of schizophrenic individuals heterozygous for Cys 311 varied between 3.6% up to 8.5% in Asian populations 32, [47] [48] [49] [50] [51] and was less frequent (1.8-5.0%) in Caucasians. 46, [52] [53] [54] [55] [56] [57] [58] Arinami et al 32 firstly reported a significantly increased allele frequency of the cysteine allele in schizophrenic Japanese patients (5.4%) compared to controls (1.8%). Furthermore, the age of onset was lower in patients with the cysteine allele and most of the allele carriers had a positive family history. But in all other association studies in Caucasians, except for one observation, 54 no associations between this variant and schizophrenia was found 46, 52, 53, [55] [56] [57] [58] [59] and all further studies in Asians also did not confirm the previous findings. 47, 49, 51, 60, 61 In contrast to Arinami et al, 32 in our sample most carriers of the cysteine allele had no family history (75.9%) compared to those with such a family history (24.1%).
We observed a non significant trend of an increased age of onset between carriers of the Cys 311 variant (mean age: 31.8 years, SD: 10.3) compared with the others (mean age 28.5 years, SD: 9.0). We did not find any homozygous individual, but this is compatible with the low allele frequency of 0.023.
In conclusion, analysis of genetic variants in the dopamine D2 receptor as predictors of neurological adverse events from antipsychotics drug treatment was a rational candidate gene approach. However, our relatively large sample did not reveal a significant impact and, as shown above, data published by others are inconsistent. Moreover the frequency of the functional amino acid variants was too rare in Caucasians to give significant results. The finding that the small number of individuals heterozygous for the Ser 310 allele had a trend to lower EPS-, AIMS-and BARS-scores may be inconsistent with in vitro data of Cravchik et al, 22 since we would expect increased adverse effects due to the less ineffective inhibition of the cAMP synthesis upon exposure to various antipsychotics. Therefore, this observation does not justify routine analysis of these DRD2 polymorphisms in psychiatric drug treatment to prevent therapeutic adverse effects in Caucasians.
Our sequencing strategy for identification of yet unknown DRD2 polymorphisms was based on the assumption, that DRD2 variants might exist which cause high susceptibility to adverse neurological effects of the antipsychotics. An alternative or complementary strategy might have been to search for variants protecting from adverse neurological effects in those patients who did not suffer from these adverse events. This approach has not been applied here since the group of patients with no or only minor adverse neurological effects was larger, and relatively large groups in the general population have already been analyzed for dopamine D2 receptor variants without revealing additional variants. Nevertheless, in the future, subgroups with resistance to adverse neurological effects might be defined and analyzed for receptor variants.
A number of problems may limit the power of this study. We cannot exclude some selection bias caused by those subjects who did not give consent to partici-pate or who left the hospitals within 7 days after admission. But we could not find a significant difference of the genotype frequencies between patients who could not be sufficiently characterized clinically and those who completed the evaluation. The study included patients receiving variable doses of different antipsychotics, a factor which could be considered by multivariate statistical analysis, but of course, power would have been greater if only one drug had been used. Moreover, the DRD2 polymorphisms may modify the response to antipsychotics treatment in their interactions with other genes such as those coding for drug metabolizing enzymes or other receptors. It is typical of many genetic polymorphisms, that their medical impact alone is mostly only moderate, but may become important in specific gene-gene or gene-environment interactions. Thus, in spite of the negative findings in this study, it is justified still to consider DRD2 variants in future pharmacogenomic studies.
One direction of further studies will be to consider multiple candidate genes and their interactions. Some authors reported an association or a tendency between dyskinesia and the dopamine D 3 receptor gene 62-66 but others could not replicate this finding. 67, 68 Of course, candidate genes may also be found in other gene groups such as those coding for acetylcholine or glutamate receptors or in genes coding free radical detoxification, drug transport, or drug biotransformation.
